Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amfetamine extended-release - Tris Pharma

Next Previous
Drug Profile

Amfetamine extended-release - Tris Pharma

Alternative Names: Amfetamine XR - Tris Pharma; AMPH EROS; Dyanavel XR; TRI 102

Latest Information Update: 21 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tris Pharma
  • Class Amphetamines; Antipsychotics; Behavioural disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder
  • Discontinued Diabetes mellitus

Most Recent Events

  • 01 Dec 2022 Amfetamine extended-release licensed to Pediatrix Therapeutics in China
  • 16 Aug 2022 Launched for Attention-deficit hyperactivity disorder (In adolescents, In children, In adults) in USA (PO)
  • 22 Jul 2022 Efficacy data from a phase-III trial for Attention-deficit hyperactivity disorder (In adults, In volunteers) released by Tris Pharma (NCT03834766)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top